

Published Transcriptional Signatures for Oncogenic Pathways

In Dry *et al* "Transcriptional pathway signatures predict MEK addiction and response to AZD6244", pathway enrichment¹ was enhanced using published transcriptional signatures relating to activity of oncogenic pathways. RAF/MEK/ERK²⁻¹², RAS¹¹⁻¹⁵, PTEN/PI3K/AKT/TOR¹⁶⁻³⁹, HR⁴⁰⁻⁶¹, P53⁶¹⁻⁶³, BER⁶⁴⁻⁷², FGFR⁷³⁻⁹⁰, multi-drug resistance mechanisms⁹¹, Other^{15,33,89,92,93}.

- Using raw data (supplementary to publication or retrieved via Gene Expression Omnibus, <http://www.ncbi.nlm.nih.gov/geo/>) or Oncomine⁹⁴ (where possible) lists were expanded by relaxing statistical filtering to t-test p<0.05
- Genelist information was stored in the **ADOPT** (A Database of Oncogenic Pathway Transcriptomes) database, enabling the intersect of genelists (controlling for the directionality of differential expression with respect to pathway activity) to be found.

1. Khatri, P. & Drghici, S. Ontological analysis of gene expression data: current tools, limitations, and open problems. *Bioinformatics* 21, 3587–3595 (2005).
2. Friedman, A. & Perrimon, N. A functional RNAi screen for regulators of receptor tyrosine kinase and ERK signalling. *Nature* 444, 230–234 (2006).
3. Furukawa, T. et al. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. *Oncogene* 25, 4831–4839 (2006).
4. Giordano, T.J. et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. *Oncogene* 24, 6646–6656 (2005).
5. Grill, C. et al. Analysis of the ERK1,2 transcriptome in mammary epithelial cells. *Biochem. J.* 381, 635–644 (2004).
6. Hoek, K.S. et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. *Pigment Cell Res.* 19, 290–302 (2006).
7. Pavey, S. et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. *Oncogene* 23, 4060–4067 (2004).
8. Schulze, A., Nicke, B., Warne, P.H., Tomlinson, S. & Downward, J. The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component. *Mol. Biol. Cell* 15, 3450–3463 (2004).
9. Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. *Nature* 439, 358–362 (2006).
10. Yamamoto, T. et al. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. *Curr. Biol.* 16, 1171–1182 (2006).
11. Kim, I.J. et al. Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations. *Carcinogenesis* 27, 392–404 (2006).
12. Bloethner S, Chen B, Hemminki K, et al. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. *Carcinogenesis* 2005;26:1224-32.
13. Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat. Genet.* 37, 48–55 (2005).
14. Tchernitsa, O.I. et al. Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. *Oncogene* 23, 4536–4555 (2004).
15. Bild, A.H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature* 439, 353–357 (2006).
16. Creighton, C.J. et al. A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors. *Oncogene* (2007) 26(32), 4648
17. Kim, J.S. et al. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. *Mol Cell Biol* (2007) 27(2), 662
18. Xu, Y. et al. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. *Cancer Res* (2006) 66(15), 7783
19. Hendrix, N.D. et al. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. *Cancer Res* (2006) 66(3), 1354
20. Lian, Z. et al. Gene expression analysis reveals a signature of estrogen receptor activation upon loss of Pten in a mouse model of endometrial cancer. *J Cell Physiol* (2006) 208(2), 255

21. Mutter, GL et al. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. *Gynecol Oncol* (2001) 83(2), 177
22. Schiekofer, S et al. Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure. *Physiol Genomics* (2006) 27(2), 156
23. Majumder, PK et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. *Nat Med* (2004) 10(6), 594
24. Palomero, T et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. *Nat Med* (2007) 13(10), 1203
25. Li, VS et al. Mutations of PIK3CA in gastric adenocarcinoma. *BMC Cancer* (2005) 5, 29
26. Packer, L et al. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. *Carcinogenesis* (2006) 27(9), 1778
27. Terragni, J et al. Phosphatidylinositol 3-kinase signaling in proliferating cells maintains an anti-apoptotic transcriptional program mediated by inhibition of FOXO and non-canonical activation of NFkappaB transcription factors. *BMC Cell Biol* (2008) 9, 6
28. Sivertsen, EA et al. PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells. *Br J Haematol* (2006) 135(1), 117
29. Hong, TM et al. Profiling the downstream genes of tumor suppressor PTEN in lung cancer cells by complementary DNA microarray. *Am J Respir Cell Mol Biol* (2000) 23(3), 355
30. Majumder, PK et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. *Proc Natl Acad Sci U S A* (2003) 100(13), 7841
31. Li, G et al. PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin. *J Biol Chem* (2006) 281(16), 10663
32. Cook, SA et al. Transcriptional effects of chronic Akt activation in the heart. *J Biol Chem* (2002) 277(25), 22528
33. Chan, G et al. Transcriptome analysis of NF-kappaB- and phosphatidylinositol 3-kinase-regulated genes in human cytomegalovirus-infected monocytes. *J Virol* (2008) 82(2), 1040
34. Cook, S.A., Matsui, T., Li, L. & Rosenzweig, A. Transcriptional effects of chronic Akt activation in the heart. *J. Biol. Chem.* 277, 22528–22533 (2002).
35. Kuhn, I. et al. Identification of AKT-regulated genes in inducible MERAkt cells. *Physiol. Genomics* 7, 105–114 (2001).
36. Matsushima-Nishiu, M. et al. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. *Cancer Res.* 61, 3741–3749 (2001).
37. Potti, A. et al. Genomic signatures to guide the use of chemotherapeutics. *Nat. Med.* 12, 1294–1300 (2006).
38. Saal, L.H. et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. *Proc. Natl. Acad. Sci. USA* 104, 7564–7569 (2007).
39. Tiwari, G., Sakaue, H., Pollack, J.R. & Roth, R.A. Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Akt-inducible gene. *Mol. Cancer Res.* 1, 475–484 (2003).
40. Lam, S et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. *J Natl Cancer Inst* (2002) 94(13), 1001
41. Kote-Jarai, Z et al. Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. *Clin Cancer Res* (2006) 12(13), 3896
42. Jang, ER et al. Analysis of ataxia-telangiectasia mutated (ATM)- and Nijmegen breakage syndrome (NBS)-regulated gene expression patterns. *J Cancer Res Clin Oncol* (2004) 130(4), 225
43. Zhou, T et al. Ataxia telangiectasia-mutated dependent DNA damage checkpoint functions regulate gene expression in human fibroblasts. *Mol Cancer Res* (2007) 5(8), 813
44. Waddell, N et al. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression. *PLoS Genet* (2008) 4(5), 1000080
45. MacLachlan, TK et al. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. *Mol Cell Biol* (2002) 22(12), 4280
46. Bae, I et al. BRCA1 regulates gene expression for orderly mitotic progression. *Cell Cycle* (2005) 4(11), 1641
47. Waddell, N et al. Characterization of the breast cancer associated ATM 7271T>G (V2424G) mutation by gene expression profiling. *Genes Chromosomes Cancer* (2006) 45(12), 1169

48. Aiyar,SE et al. Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells. *Int J Biol Sci* (2007) 3(7), 486
49. Jazaeri AA et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. *JNCI* (2002) 94(13), 990
50. Bane AL et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. *Breast Cancer Res Treat.* (2008) , online
51. Tone,AA et al. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. *Clin Cancer Res* (2008) 14(13), 4067
52. Kote-Jarai,Z et al. Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. *Clin Cancer Res* (2004) 10(3), 958
53. van 't Veer,LJ et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* (2002) 415(6871), 530
54. Pawitan,Y et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. *Breast Cancer Res* (2005) 7(6), 953
55. Hedenfalk,I et al. Gene-expression profiles in hereditary breast cancer. *N Engl J Med* (2001) 344(8), 539
56. Stankovic,T et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. *Blood* (2004) 103(1), 291
57. Hedenfalk,I et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. *Proc Natl Acad Sci U S A* (2003) 100(5), 2532
58. Berns,EM et al. Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features. *Br J Cancer* (2001) 85(4), 538
59. Aiyar,SE et al. Regulation of clustered gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells. *Oncogene* (2007) 26(18), 2543
60. Chen,S et al. Stable siRNA-mediated silencing of ATM alters the transcriptional profile of HeLa cells. *Biochem Biophys Res Commun* (2004) 317(4), 1037
61. Greiner,TC et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. *Proc Natl Acad Sci U S A* (2006) 103(7), 2352
62. Sorlie,T et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc Natl Acad Sci U S A* (2003) 100(14), 8418
63. Miller, L.D. et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. *Proc. Natl. Acad. Sci. USA* 102, 13550–13555 (2005).
64. Zingarelli B et al. Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. *Mol Med.* (2003) 9(5-8), 143
65. Cardoso,RS et al. Differential gene expression in gamma-irradiated BALB/3T3 fibroblasts under the influence of 3-aminobenzamide, an inhibitor of parp enzyme. *Mutat Res* (2002) 508(1-2), 33
66. Ogino H et al. Loss of PARP1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. *BMC Genomics.* (2007) 8, 227
67. Martin-Oliva,D et al. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. *Cancer Res* (2006) 66(11), 5744
68. Simbulan-Rosenthal,CM et al. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. *Proc Natl Acad Sci U S A* (2000) 97(21), 11274
69. Hemberger,M et al. Parp1-deficiency induces differentiation of ES cells into trophoblast derivatives. *Dev Biol* (2003) 257(2), 371
70. Vanderauwera,S et al. Silencing of poly(ADP-ribose) polymerase in plants alters abiotic stress signal transduction. *Proc Natl Acad Sci U S A* (2007) 104(38), 15150
71. Carrillo,A et al. Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. *Nucleic Acids Res* (2004) 32(2), 757
72. Saenz,L et al. Transcriptional regulation by poly(ADP-ribose) polymerase-1 during T cell activation. *BMC Genomics* (2008) 9, 171
73. Dailey,L et al. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. *J Cell Biol* (2003) 161(6), 1053
74. Fanganiello,RD et al. Apert p.Ser252Trp mutation in FGFR2 alters osteogenic potential and gene expression of cranial periosteal cells. *Mol Med* (2007) 13(7-8), 422

75. Rosty,C et al. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. *Mol Cancer* (2005) 4(1), 15
76. Jackson,TA et al. Differential regulation of cell growth and gene expression by FGF-2 and FGF-4 in pituitary lactotroph GH4 cells. *Mol Cell Endocrinol* (2006) 247(1-2), 183
77. Jukkola,T et al. FGF regulated gene-expression and neuronal differentiation in the developing midbrain-hindbrain region. *Dev Biol* (2006) 297(1), 141
78. Lioubinski,O et al. FGF signalling controls expression of vomeronasal receptors during embryogenesis. *Mech Dev* (2006) 123(1), 17
79. Lu,SY et al. FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development. *Am J Physiol Cell Physiol* (2008) 294(5), 1242
80. Fu,L et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. *Endocrinology* (2004) 145(6), 2594
81. Greber,B et al. Fibroblast growth factor 2 modulates transforming growth factor beta signaling in mouse embryonic fibroblasts and human ESCs (hESCs) to support hESC self-renewal. *Stem Cells* (2007) 25(2), 455
82. Zhu,L et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. *Mol Cancer Ther* (2005) 4(5), 787
83. Ambrosetti,D et al. Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transcription in osteoblasts. *Mol Cell Biol* (2008) 28(15), 4759
84. Dell'Era,P et al. Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. *Oncogene* (2002) 21(15), 2433
85. Quarto,N et al. Gene profiling of cells expressing different FGF-2 forms. *Gene* (2005) 356, 49
86. Hortala,M et al. Identification of c-Jun as a critical mediator for the intracrine 24 kDa FGF-2 isoform-induced cell proliferation. *Int J Cancer* (2005) 114(6), 863
87. Lu,J et al. Identification of FGF10 targets in the embryonic lung epithelium during bud morphogenesis. *J Biol Chem* (2005) 280(6), 4834
88. Bernard-Pierrot,I et al. Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor. *Oncogene* (2004) 23(57), 9201
89. Yoshida,E et al. Neuroprotective gene expression profiles in ischemic cortical cultures preconditioned with IGF-1 or bFGF. *Brain Res Mol Brain Res* (2004) 131(1-2), 33
90. Mansukhani,A et al. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. *J Cell Biol* (2005) 168(7), 1065
91. Zhang, L., Strong, J.M., Qiu, W., Lesko, L.J. & Huang S.M. Scientific Perspectives on Drug Transporters and Their Role in Drug Interactions. *Mol. Pharm.* 3, 62–69 (2006).
92. Juhász G et al. Gene expression profiling identifies FKBP39 as an inhibitor of autophagy in larval *Drosophila* fat body. *Cell Death Differ.* (2007) 14(6), 1181
93. Kanzawa,T et al. Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. *Oncogene* (2005) 24(6), 980
94. Rhodes DR et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. *Neoplasia*. (2004) 6(1), 1-6